Logo image of PTPI

PETROS PHARMACEUTICALS INC (PTPI) Stock Fundamental Analysis

NASDAQ:PTPI - Nasdaq - US71678J2096 - Common Stock

0.32  +0.02 (+6.63%)

After market: 0.3141 -0.01 (-1.84%)

Fundamental Rating

2

PTPI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. PTPI may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, PTPI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year PTPI has reported negative net income.
In the past year PTPI has reported a negative cash flow from operations.
In the past 5 years PTPI always reported negative net income.
In the past 5 years PTPI reported 4 times negative operating cash flow.
PTPI Yearly Net Income VS EBIT VS OCF VS FCFPTPI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

PTPI has a Return On Assets of -144.12%. This is amonst the worse of the industry: PTPI underperforms 83.87% of its industry peers.
PTPI's Return On Equity of -956.75% is on the low side compared to the rest of the industry. PTPI is outperformed by 83.87% of its industry peers.
Industry RankSector Rank
ROA -144.12%
ROE -956.75%
ROIC N/A
ROA(3y)-38.68%
ROA(5y)-40.24%
ROE(3y)-85.33%
ROE(5y)-155.84%
ROIC(3y)N/A
ROIC(5y)N/A
PTPI Yearly ROA, ROE, ROICPTPI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

PTPI's Gross Margin of 74.74% is amongst the best of the industry. PTPI outperforms 81.18% of its industry peers.
In the last couple of years the Gross Margin of PTPI has declined.
PTPI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.69%
GM growth 5Y-2.77%
PTPI Yearly Profit, Operating, Gross MarginsPTPI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

0

2. Health

2.1 Basic Checks

PTPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
PTPI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PTPI has more shares outstanding
The debt/assets ratio for PTPI has been reduced compared to a year ago.
PTPI Yearly Shares OutstandingPTPI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
PTPI Yearly Total Debt VS Total AssetsPTPI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -10.07, we must say that PTPI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.07, PTPI is doing worse than 76.34% of the companies in the same industry.
PTPI has a Debt/Equity ratio of 1.58. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.58, PTPI is doing worse than 76.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.58
Debt/FCF N/A
Altman-Z -10.07
ROIC/WACCN/A
WACC7.89%
PTPI Yearly LT Debt VS Equity VS FCFPTPI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M

2.3 Liquidity

PTPI has a Current Ratio of 0.85. This is a bad value and indicates that PTPI is not financially healthy enough and could expect problems in meeting its short term obligations.
PTPI's Current ratio of 0.85 is on the low side compared to the rest of the industry. PTPI is outperformed by 90.32% of its industry peers.
A Quick Ratio of 0.74 indicates that PTPI may have some problems paying its short term obligations.
PTPI's Quick ratio of 0.74 is on the low side compared to the rest of the industry. PTPI is outperformed by 88.17% of its industry peers.
Industry RankSector Rank
Current Ratio 0.85
Quick Ratio 0.74
PTPI Yearly Current Assets VS Current LiabilitesPTPI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

5

3. Growth

3.1 Past

The earnings per share for PTPI have decreased strongly by -48.10% in the last year.
PTPI shows a strong growth in Revenue. In the last year, the Revenue has grown by 46.16%.
Measured over the past years, PTPI shows a very negative growth in Revenue. The Revenue has been decreasing by -16.15% on average per year.
EPS 1Y (TTM)-48.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.13%
Revenue 1Y (TTM)46.16%
Revenue growth 3Y-15.24%
Revenue growth 5Y-16.15%
Sales Q2Q%-5.87%

3.2 Future

The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
PTPI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.86% yearly.
EPS Next Y58.64%
EPS Next 2Y33.73%
EPS Next 3Y21.34%
EPS Next 5Y14.87%
Revenue Next Year-29.45%
Revenue Next 2Y-15.69%
Revenue Next 3Y-10.88%
Revenue Next 5Y23.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PTPI Yearly Revenue VS EstimatesPTPI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
PTPI Yearly EPS VS EstimatesPTPI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

1

4. Valuation

4.1 Price/Earnings Ratio

PTPI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PTPI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTPI Price Earnings VS Forward Price EarningsPTPI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTPI Per share dataPTPI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

PTPI's earnings are expected to grow with 21.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.73%
EPS Next 3Y21.34%

0

5. Dividend

5.1 Amount

PTPI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PETROS PHARMACEUTICALS INC

NASDAQ:PTPI (1/21/2025, 8:22:14 PM)

After market: 0.3141 -0.01 (-1.84%)

0.32

+0.02 (+6.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners2.16%
Inst Owner Change0%
Ins Owners6.83%
Ins Owner Change0%
Market Cap3.20M
Analysts82.86
Price Target1.02 (218.75%)
Short Float %6.9%
Short Ratio0.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.14%
Min EPS beat(2)-79.18%
Max EPS beat(2)52.89%
EPS beat(4)1
Avg EPS beat(4)-35.9%
Min EPS beat(4)-102.26%
Max EPS beat(4)52.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)7.53%
Min Revenue beat(2)-0.25%
Max Revenue beat(2)15.32%
Revenue beat(4)2
Avg Revenue beat(4)69.07%
Min Revenue beat(4)-6.35%
Max Revenue beat(4)267.58%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)59.26%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.31
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.88
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS1.02
BVpS0.31
TBVpS-0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -144.12%
ROE -956.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.74%
FCFM N/A
ROA(3y)-38.68%
ROA(5y)-40.24%
ROE(3y)-85.33%
ROE(5y)-155.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.69%
GM growth 5Y-2.77%
F-Score4
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 1.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.85
Quick Ratio 0.74
Altman-Z -10.07
F-Score4
WACC7.89%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.13%
EPS Next Y58.64%
EPS Next 2Y33.73%
EPS Next 3Y21.34%
EPS Next 5Y14.87%
Revenue 1Y (TTM)46.16%
Revenue growth 3Y-15.24%
Revenue growth 5Y-16.15%
Sales Q2Q%-5.87%
Revenue Next Year-29.45%
Revenue Next 2Y-15.69%
Revenue Next 3Y-10.88%
Revenue Next 5Y23.86%
EBIT growth 1Y-74.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.16%
OCF growth 3YN/A
OCF growth 5YN/A